Fulcrum Therapeutics (NASDAQ: FULC) insider transactions
In the twelve months to 10 November 2026, executives and directors of Fulcrum Therapeutics reported 8 open-market sales of 4,241,591 shares ($59.0m) and 6 open-market purchases of 417,562 shares ($1.5m), by 6 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 17 July 2026 | Tang Kevin | — | Open-market purchase | +50,945 | $3.52 | 7,080,945 | Form 4 |
| 16 July 2026 | Tang Kevin | — | Open-market purchase | +116,671 | $3.56 | 7,030,000 | Form 4 |
| 15 July 2026 | Tang Capital Management Llc | — | Open-market purchase | +107,377 | $3.56 | 6,913,329 | Form 4 |
| 14 July 2026 | Tang Capital Management Llc | — | Open-market purchase | +53,651 | $3.56 | 6,730,000 | Form 4 |
| 14 July 2026 | Tang Capital Management Llc | — | Open-market purchase | +75,952 | $3.58 | 6,805,952 | Form 4 |
| 13 July 2026 | Tang Capital Management Llc | — | Open-market purchase | +12,966 | $3.54 | 6,676,349 | Form 4 |
| 26 June 2026 | Ezekowitz Alan | Director | Open-market sale | −18,000 | $3.65 | 10,927 | Form 4 |
| 2 February 2026 | Gould Robert J | Director | Open-market sale | −15,000 | $10.72 | 454,864 | Form 4 |
| 2 January 2026 | Gould Robert J | Director | Open-market sale | −15,000 | $11.87 | 469,864 | Form 4 |
| 15 December 2025 | Oltmans Curtis Gale | Chief Legal Officer | Open-market sale | −3,452 | $12.92 | 10,252 | Form 4 |
| 8 December 2025 | RA Capital Healthcare Fund LP | — | Open-market sale | −1,377,020 | $13.33 | 8,852,079 | Form 4 |
| 8 December 2025 | RA Capital Healthcare Fund LP | — | Open-market sale | −2,706,397 | $14.28 | 6,145,682 | Form 4 |
| 8 December 2025 | RA Capital Healthcare Fund LP | — | Open-market sale | −91,722 | $14.98 | 6,053,960 | Form 4 |
| 19 November 2025 | Gould Robert J | Director | Open-market sale | −15,000 | $11.03 | 484,864 | Form 4 |
| 8 May 2025 | Tourangeau Greg | Principal Accounting Officer | Open-market sale | −498 | $5.06 | 14,062 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Fulcrum Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.